5,000 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Acquired by Atlas Capital Advisors LLC

Atlas Capital Advisors LLC bought a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 5,000 shares of the biopharmaceutical company’s stock, valued at approximately $34,000.

Other institutional investors have also recently bought and sold shares of the company. Trust Co. of Vermont grew its stake in shares of Ocular Therapeutix by 20.0% during the fourth quarter. Trust Co. of Vermont now owns 6,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,000 shares during the period. Victory Capital Management Inc. bought a new stake in Ocular Therapeutix during the fourth quarter worth about $45,000. Bayesian Capital Management LP bought a new stake in shares of Ocular Therapeutix during the 1st quarter worth approximately $94,000. Ameritas Investment Partners Inc. raised its holdings in shares of Ocular Therapeutix by 39.4% in the 1st quarter. Ameritas Investment Partners Inc. now owns 11,531 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 3,257 shares during the period. Finally, Dudley & Shanley Inc. bought a new stake in Ocular Therapeutix in the 2nd quarter valued at $111,000. Institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Trading Up 3.0 %

Shares of OCUL stock opened at $8.82 on Friday. Ocular Therapeutix, Inc. has a 12-month low of $2.00 and a 12-month high of $11.31. The company has a quick ratio of 16.55, a current ratio of 16.64 and a debt-to-equity ratio of 0.18. The company has a 50 day moving average of $7.88 and a 200-day moving average of $7.47. The firm has a market cap of $1.37 billion, a P/E ratio of -6.53 and a beta of 1.30.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.04). Ocular Therapeutix had a negative return on equity of 52.75% and a negative net margin of 226.46%. The business had revenue of $16.40 million for the quarter, compared to analysts’ expectations of $15.85 million. During the same quarter in the previous year, the firm earned ($0.27) earnings per share. Ocular Therapeutix’s quarterly revenue was up 7.9% compared to the same quarter last year. Sell-side analysts anticipate that Ocular Therapeutix, Inc. will post -1.02 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on OCUL shares. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Ocular Therapeutix in a research report on Thursday, August 1st. JMP Securities decreased their target price on shares of Ocular Therapeutix from $24.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 8th. Piper Sandler reiterated an “overweight” rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Friday, June 21st. TD Cowen cut shares of Ocular Therapeutix from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 21st. Finally, Robert W. Baird decreased their price objective on shares of Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.67.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.